|
KMID : 0354719940180030270
|
|
Journal of Korean Diabetes Association
1994 Volume.18 No. 3 p.270 ~ p.276
|
|
|
Effects of Acipimox(Olbetam) Treatment on Lipid and Glucose Metabolism in Hyperlipidemic Patients with NIDDM
|
|
한제호
송기호/유순집/이종민/손현식/윤건호/강무일/이광우/손호형
|
|
|
Abstract
|
|
|
Background :
@EN Hyperlipidemia in NIDDM patients is a major risk factor of atherogenesis, and its proper management is an important issue to decrease the mortality due to macroveascular complications. Acipimox, newly developed nicotinic acid derivative, is
known to
have safe and long-lasting antilipolytic activity. The purpose of this study was to evaluate the effects of acipimox on lipid and glucose metabolism in hyperlipidemic patients with NIDDM.
@ES Methods :
@EN The effects of acipimox treatment were evaluated on the changes of lipid and glucose metabolism after 8 weeks of administration, and its side effects were also evaluated in 24 hyperlipidemic patients with NIDDM.
@ES Results:
@EN 1) Serum cholesterol concentration was decreased and HDL cholesterol concentration was increased significantly after acipimox treatment. Serum triglyceride concentration was also decreased without statistical significance following acipimox
administration.
2) Fasting serum glucose level was significantly decreased. But postpriandial glucose and glycated hemoglobin levels were not changed significantly after acipimox treatment.
3) Serm free fatty acid level was significantly decreased after acipimox treatment.
4) Serum Apo AI level was increased, and Apo B and lipoprotein (a) levels were decreased significantly following treatment.
5) Among 24 patients, we cold not find any other side effects except mild and transient pruritus in one patient.
@ES Conclusion:
@EN Acipimox is thought to be an effective and safe drug for the treatment of hyperlipidemia in patients with non insulin-dependent diabetes mellitus.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|